The subtle threat of human papilloma virus: A comprehensive overview

Oncogenic viruses that flourish in people as well as animals can produce malignances. With almost more than 200 different forms, human papillomavirus (HPV) is the main oncogenic virus present in the reproductive tract. The most common form is HPV 16; large amounts of this type have been found in warty and basaloid vulvar cancer. Particularly HPV strains 6, 11, and 18, which are linked to vaginal cancer, women who participate in sexual activity have a higher risk of obtaining HPV. Comprising five species and a 7.9 kilobase genome, HPV consists in 120 identified strains. Men have more HPV infections than women; 11.5 % of men and 3.2 % of women get infected with HPV. Men who engage in oral intercourse with two or more partners had the highest prevalence of oral HPV infection; high-risk oral HPV is linked with factors including cigarette and marijuana usage. Because of concurrent genital HPV infection, women had three times higher oral HPV infection rate. As HPV DNA can transform normal breast cells into a unique and self-sustaining phenotype, conision is a definitive sign of HPV infection. Linked to HPV, cancer is a major worldwide burden; several types of cancers in humans are brought on by HPV infection. Cryotherapy for cervical intra epithelial neoplasia (CIN), photodynamic therapy (PDT), prodrug 5-aminolevulinic acid (ALA)-mediated PDT, HPV inactivation by antiviral medicine and salicylic acid, and medications against cancer and monoclonal antibodies comprise treatment and preventive techniques. Among the FDA-approved treatments for several malignancies include Bleomycin sulfates, gemcitabine and cisplatin, topotecan hydrochloride, bevacizumab, pembrolizumab, platinum and fluorouracil, and durvalumab. This paper offers a thorough review of HPV-related cervical cancer addressing issues including pathogenesis, laboratory diagnosis, treatment, prevention, infection, epidemiology, global effect.